InspireMD

InspireMD Book Value per Share

The Book Value per Share of InspireMD (NSPR) as of Oct 16, 2026 is 1.32 USD. In the previous year, Book Value per Share was 0.86 USD — a change of 52.97% (higher).

Book Value per Share

1.32USD

YoY

52.97%

Last updated:

Book Value per Share of InspireMD is 2025 1.32 USD. Book Value per Share of InspireMD was 2024 0.86 USD. It decreases by 52.97% higher compared to the previous year.

The InspireMD Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
0.21 USD
Jan 1, 2019
0.13 USD
Jan 1, 2020
0.29 USD
Jan 1, 2021
0.80 USD
Jan 1, 2022
0.41 USD
Jan 1, 2023
0.94 USD
Jan 1, 2024
0.86 USD
Jan 1, 2025
1.32 USD
The InspireMD Book Value per Share history
YEARBook Value per ShareYoY
1.32USD+52.97%
0.86USD-8.65%
0.94USD+127.11%
0.41USD-48.13%
0.80USD+175.69%
0.29USD+125.95%
0.13USD-38.57%
0.21USD+221.34%
0.07USD-32.58%
0.10USD-237.30%
-0.07USD+5.71%
-0.07USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InspireMD Stock analysis

What does InspireMD do? InspireMD Inc, listed on the stock market with ticker NSPR and ISIN US45779A8466, is a medical device company based in Tel Aviv-Yafo, Israel. The company operates within the Health Care sector, specifically in the Health Care industry. InspireMD has 127 employees and went public through an IPO on April 12, 2013. Its website is http://www.inspiremd.com/. The company focuses on developing and commercializing stent platform technology for treating complex vascular and coronary diseases. InspireMD's MicroNet is a micron mesh sleeve designed to wrap around a stent, providing embolic protection during stenting procedures. The company also offers the CGuard carotid embolic prevention system, which integrates MicroNet with a self-expandable nitinol stent for carotid artery applications. Additionally, InspireMD markets the MGuard Prime Embolic Protection System, a bare-metal cobalt-chromium stent, for coronary disease treatment in the European Union. The MGuard Prime EPS is also intended for use in patients with acute coronary syndromes, including acute myocardial infarction and saphenous vein graft coronary interventions. The company is developing a neurovascular flow diverter called NGuard, an endovascular device. InspireMD's technology aims to enhance safety and efficacy in vascular and coronary interventions by preventing embolic events during stent placement. InspireMD is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InspireMD stock

Book Value per Share of InspireMD is 1.32 USD in 2025.

Book Value per Share of InspireMD changed from 0.86 USD to 1.32 USD, representing a 52.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share InspireMD since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — InspireMD

All Key Metrics — InspireMD